26
total announcements
INDOCO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹2,180 Cr
P/E (TTM)
739.1
P/E (Forward)
19.5
EPS (TTM)
₹0.32
52W Low
₹162.19
52W High
₹291.00
Dividend Yield
0.08%
Beta
0.62
Price / Book
2.1
Debt / Equity
116.9
Revenue (TTM)
₹1,873 Cr
Gross Margin
69.85%
Operating Margin
1.39%
Indoco Remedies Limited
Indoco Remedies Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended September 30, 2026.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about mandatory furnishing of PAN, KYC, and Bank details as per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, for shareholders holding shares in physical mode.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the incorporation of a Wholly Owned subsidiary, Warren Lifesciences Private Limited, under the provisions of the Companies Act, 2013.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will remain closed from 01st October, 2026 until 48 hours after the declaration of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding ESG rating assigned by Crisil ESG Ratings & Analytics Limited.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the approval of the Committee of Executive Directors for the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited.
Indoco Remedies Limited
Indoco Remedies Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results.
Indoco Remedies Limited
Indoco Remedies Limited held its 79th Annual General Meeting on September 17, 2026, through Video Conferencing (VC) / Other Audio Video Means (OAVM), where the members approved various resolutions, including the appointment of a Director, re-appointment of the Managing Director, and increase in borrowing limits.
Indoco Remedies Limited
Indoco Remedies Limited announced that its solid dosages manufacturing facility in Goa (Plant I) was inspected by the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) from September 7 to September 9, 2026. The inspection concluded with no critical or major observations.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange regarding USFDA inspection at its manufacturing facility at Plant II (Sterile) located at Goa, where seven observations were noted in Form 483.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the execution of a Deed of Conveyance for the sale of its plot of land to Kalpataru Townships Private Limited for Rs. 64,00,00,000. The sale would not impact the company's business operations.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about Newspaper Advertisement regarding Notice convening the 79th AGM and E-voting Information.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange regarding 'Business Responsibility & Sustainability report for the financial year 2025-2026'.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026, along with the Annual Report 2025-2026.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange that the Record Date for the purpose of Dividend is 10-Sep-2026, and the Company has fixed Thursday, 10th September, 2026 as the cut-off date for the purpose of remote e-voting and e-voting during the AGM.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the publication of a newspaper advertisement for its 79th Annual General Meeting (AGM) to be held on September 17, 2026, through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The AGM notice and annual report for the financial year 2025-2026 will be available on the company's website and stock exchange websites.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the transcript of Earnings Conference Call held on 28th July, 2026, in respect of Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026.
Indoco Remedies Limited
Indoco Remedies Limited has published unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026, showing a net profit of Rs. 8,232 lakhs and a total comprehensive income of Rs. 8,187 lakhs.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange about the link to the recording of their earnings conference call for the quarter ended 30th June, 2026, which is available on their website.
Indoco Remedies Limited
Indoco Remedies Limited has informed the Exchange regarding the appointment of Mr. Sudhir Kadam as Senior Management Personnel designated as Sr. Vice President (Human Capital) of the company, effective from July 28, 2026. The Board of Directors has also re-appointed Ms. Aditi Panandikar as a Managing Director of the Company for a period of 5 years commencing from February 15, 2027, subject to the approval of the Shareholders at the ensuing 79th Annual General Meeting.